CTLA4 and juvenile idiopathic arthritis: To date, CTLA4 Ig (abatacept), which binds to CD80/CD86 and inhibits inflammatory T cell activation, has been approved by the US Food and Drug Administration to treat RA, juvenile idiopathic arthritis, and active psoriatic arthritis [63].